Navigation Links
Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
Date:3/27/2008

87, additional projects under the Wyeth collaboration continue to be pursued for undisclosed indications.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single- chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's lead product candidate, TRU-015, has completed a Phase 2b clinical trial for the treatment of rheumatoid arthritis and additional projects under the Wyeth collaboration are being pursued for the treatment of Systemic Lupus Erythematosus and other undisclosed indications. Trubion's proprietary product candidate, TRU-016, is a novel CD37-targeted therapy for the treatment of B-cell malignancies currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.

Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the company's future clinical development programs and the timing thereof, the company's expected financial and operating results, future clinical development plans, the details of the clinical trials and the results and timing thereof, and the timing of regulatory applicat
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
2. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
3. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
4. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
5. Metabolex Initiates Phase 1 Trial of MBX-2982
6. Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes
7. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
8. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
9. Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)
10. Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid
11. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)...  Dr. Stephen Loyd , a recovering substance ... National Recovery Month, stars in a new television ad ... advocates were also joined by a Los ... her fiancée because of a preventable error in surgery ... of crack cocaine abuse. Proposition 46 would identify doctors ...
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire-iReach/ -- ChemImage announced ... discussing improvements in the development of imaging ... both normal and diseased tissue that minimizes ... surgical procedures, lowers surgical costs and potentially ... The clinical and scientific ...
(Date:9/17/2014)... , Sept. 17, 2014 Prostate Oncology ... awareness campaign to educate men about new imaging ... of the prostate. Annually, a million men undergo ... the rectum. Multi-parametric MRI (MP-MRI) of the prostate gland ... (CSPC). Men need to be fully informed of ...
Breaking Medicine Technology:Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3
(Date:9/18/2014)... 2014 First Choice Emergency Room ... in the United States, named Douglas J. Harrison, DO ... facility. , “We are pleased to welcome Dr. ... of our new Missouri City-Lakes facility,” said Dr. James ... Room. , Dr. Harrison received his undergraduate degree ...
(Date:9/18/2014)... N-Zyme Scientifics LLC achieved a major developmental milestone ... mere 8 months after company startup. Its novel product ... enzyme used in the “Biologics” industry for discovery and ... pathology on Mass Spec devices. PRIME™ is being sold ... market (PNGase F PRIMETM). N-Zyme is currently evaluating ...
(Date:9/17/2014)... Recently, BambooIndustry.com, an outstanding company in the bamboo industry, ... There are more than 1000 items in this range. To ... for these useful items. Each of them is now offered ... “We are very proud to unveil the new range of ... are made with natural materials by experienced workers. They are ...
(Date:9/17/2014)... Recently, UWDress.com, an innovative company that ... occasion outfits, has released its 2014 empire waist ... has launched a big sale for these new and ... deeply discounted rates, from 15 to 65 percent off. ... on using comfortable to wear materials. Its elegant items ...
(Date:9/17/2014)... (PRWEB) September 18, 2014 Dr. Shalev is ... came to Houston to study at the University of Texas, ... While studying she realized her real passion lay in dentistry, ... Surgery from the University of Texas Health Science Center at ... dentistry, and is a member of The Greater Houston Dental ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Douglas J. Harrison as Medical Director of Missouri City - Lakes, Texas Facility 2Health News:N-Zyme Scientifics Announces Successful Product Launch 2Health News:More Than 1000 Items Added To BambooIndustry.com’s Bamboo Flooring Collection 2Health News:2014 Empire Waist Evening Dress Collection Now Unveiled At UWDress.com 2
... to provide improved accessibility and expanded contentORANGEBURG, S.C., ... company, announces the launch of its updated website. ... URL and can be found at http://www.polymathiclabs.com ... including more information about Polymathic,s services, capabilities, and ...
... Hard to Treat Diseases (HTDS) www.htdsmedical.com the ... Chem (Formerly ReNuYu Biochem) intends to recapitalize to 5 ... the pending China Bio Chem merger. Consideration for Slavica ... amongst all doctors involved in Belgrade Serbia research. Key ...
... TORONTO, Jan. 8 /PRNewswire-FirstCall/ - Med-Emerg International Inc. (OTCBB:MDER) ... is pleased to announce that its shareholders have voted ... (the "Arrangement") with AIM Health Group Inc. ("AIM") at ... today. In excess of 90% of the votes cast ...
... that work, CDC officials stress , , THURSDAY, Jan. 8 (HealthDay ... is resistant to the popular antiviral drug Tamiflu, but government ... , The fact that the flu season so far has ... particular flu virus, has health officials adopting a watchful attitude ...
... May Be Revealed Friday, January 9 WASHINGTON, Jan. ... (SEIU) President Andy Stern convened a conference call ... the forced transfer of 65,000 nursing home and ... (UHW), its third largest affiliate, but delayed the ...
... shape new treatments for secondary pneumoniaMEMPHIS, Tenn., Jan. ... Hospital have demonstrated a more effective treatment for ... antibiotics clindamycin and azithromycin, which kill bacteria by ... a standard first-line treatment with the "beta-lactam" antibiotic ...
Cached Medicine News:Health News:Polymathic Analytical Labs Launches New Website 2Health News:Hard To Treat Diseases (HTDS) Recapitalization 2Health News:Shareholders of Med-Emerg International Inc. approve plan of arrangement with AIM Health Group Inc. 2Health News:Common Flu Strain Resistant to Popular Antiviral Drug 2Health News:Common Flu Strain Resistant to Popular Antiviral Drug 3Health News:SEIU Decision to Force Transfer of Long-Term Care Members Out of United Healthcare Workers Delayed 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: